Browsing by author "Wennerberg, Erik"
Now showing items 1-6 of 6
-
CD73 Blockade Promotes Dendritic Cell Infiltration of Irradiated Tumors and Tumor Rejection.
Wennerberg, E; Spada, S; Rudqvist, N-P; Lhuillier, C; Gruber, S; et al. (AMER ASSOC CANCER RESEARCH, 2020-04-01)The ability of focal radiotherapy to promote priming of tumor-specific CD8+ T cells and increase responses to immunotherapy is dependent on infiltration of the tumor by Batf3-dependent conventional dendritic cell type 1 ... -
Exercise reduces immune suppression and breast cancer progression in a preclinical model.
Wennerberg, E; Lhuillier, C; Rybstein, MD; Dannenberg, K; Rudqvist, N-P; et al. (Impact Journals, LLC, 2020-01-28)Exercise is associated with favorable changes in circulating immune cells and improved survival in early-stage breast cancer patients, but the mechansims remain to be fully elucidated. Preclinical studies indicate that ... -
Expression of the mono-ADP-ribosyltransferase ART1 by tumor cells mediates immune resistance in non-small cell lung cancer.
Wennerberg, E; Mukherjee, S; Spada, S; Hung, C; Agrusa, CJ; et al. (AMER ASSOC ADVANCEMENT SCIENCE, 2022-03-16)Most patients with non-small cell lung cancer (NSCLC) do not achieve durable clinical responses from immune checkpoint inhibitors, suggesting the existence of additional resistance mechanisms. Nicotinamide adenine dinucleotide ... -
Hallmarks of Resistance to Immune-Checkpoint Inhibitors.
Karasarides, M; Cogdill, AP; Robbins, PB; Bowden, M; Burton, EM; et al. (AMER ASSOC CANCER RESEARCH, 2022-04-01)Immune-checkpoint inhibitors (ICI), although revolutionary in improving long-term survival outcomes, are mostly effective in patients with immune-responsive tumors. Most patients with cancer either do not respond to ICIs ... -
Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade.
Appleton, E; Hassan, J; Chan Wah Hak, C; Sivamanoharan, N; Wilkins, A; et al. (FRONTIERS MEDIA SA, 2021-10-18)Cancer patients with low or absent pre-existing anti-tumour immunity ("cold" tumours) respond poorly to treatment with immune checkpoint inhibitors (ICPI). In order to render these patients susceptible to ICPI, initiation ... -
Targeting Cancer Heterogeneity with Immune Responses Driven by Oncolytic Peptides.
Vitale, I; Yamazaki, T; Wennerberg, E; Sveinbjørnsson, B; Rekdal, Ø; et al. (CELL PRESS, 2021-01-11)Accumulating preclinical and clinical evidence indicates that high degrees of heterogeneity among malignant cells constitute a considerable obstacle to the success of cancer therapy. This calls for the development of ...